Parts of this article (those related to clinical trial phase III) need to be updated. Please help update this article to reflect recent events or newly available information. (September 2016)
This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (June 2019)

Cevira is in development as a local treatment for Cervical intraepithelial neoplasia lesions and human papilloma virus (HPV) of the cervix without damaging healthy tissue. With Cevira, Photocure aims to develop the first non-surgical treatment for precancerous cervical lesions using photodynamic therapy (PDT). Cevira treatment is administered locally and remains in contact with the cervix to deliver treatment for up to 24 hours. A cup holds the ointment against the cervix for initial absorption. After a few hours, a light source within the cup emits light at a specific wavelength so the Active Pharmaceutical Ingredient, hexylaminolevulinate (HAL), reacts with the tissue.[1][2]

References

  1. ^ "Photodynamic Device Developed to Treat Precancerous Cervical Lesions". Medical Advice Network. 18 March 2011. Retrieved 2013-06-06.
  2. ^ Fontanazza, Maria (April 18, 2011). "Drug and Light Join Forces to Fight Precancerous Lesions". MDDI. Archived from the original on April 14, 2013. Retrieved 2013-06-06.
Category